Evidence map›Paper›PMID 41847306›Full record

ReviewDrug design, development and therapy2026

Baicalin as a Multifunctional Regulator of Gut Health: Integrative Mechanisms Involving Inflammation, Barrier Integrity, and Gut-Organ Axis.

Weiyu Zhu, Chaoyi Jia, Tianyuan Fei, Zhaoyue Chen, Zhanyu Lin, Yu Pan, Guobing Ma, Fengjun Ma

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weiyu ZhuDepartment of Traditional Chinese College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Chaoyi JiaDepartment of Traditional Chinese College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Tianyuan FeiDepartment of Traditional Chinese College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Zhaoyue ChenDepartment of Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Zhanyu LinDepartment of Traditional Chinese College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Yu PanDepartment of Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Guobing MaDepartment of Traditional Chinese College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Fengjun MaDepartment of Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intestinal health is sustained by coordinated control of mucosal immunity, epithelial barrier integrity, and the gut microbiota and its metabolites. Disruption of these tightly coupled systems contributes to a wide spectrum of disorders, ranging from infectious enteritis and inflammatory bowel disease (IBD) to ischemia-reperfusion injury and metabolic dysfunction with extra-intestinal sequelae. Baicalin (BAI), a major flavonoid from Scutellaria baicalensis, has emerged as a multi-level regulator of gut homeostasis. Across diverse preclinical models, BAI attenuates inflammatory signaling and frequently converges on NF-κB-centered networks; it also rebalances immune responses by modulating macrophage polarization and T-cell subsets, limits oxidative and ferroptotic damage through cytoprotective programs, and restores barrier function by preserving tight junctions and mucus-layer defenses. In parallel, BAI remodels microbial community structure and microbial metabolites, including short-chain fatty acids and bile-acid signaling, providing a plausible basis for benefits along gut-organ axes such as the gut-liver and gut-metabolic axes. This review integrates mechanistic evidence across these three pillars and highlights key translational gaps, including limited oral bioavailability, incomplete causal validation of proposed targets, and the need to disentangle BAI from active metabolites. We further discuss derivative design, formulation, and combination strategies to improve exposure and accelerate clinical translation.

Indexed as

FlavonoidsGastrointestinal MicrobiomeInflammationAnimalsHumansIntestinal Barrier FunctionbaicalinFlavonoidsbaicalinbarrier integritygut healthgut-organ axisinflammation

Identifiers

PMID41847306
PMCPMC12991292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.